NovoCure (NVCR) Gross Profit (2014 - 2026)

NovoCure has disclosed Gross Profit across 13 years of filings, most recently posting $135.1 million for Q1 2026.

• Gross Profit for Q1 2026 came in at $135.1 million, up 16.01% year-over-year; the trailing twelve-month figure through Mar 2026 was $507.1 million (up 5.72% YoY), and the FY2025 annual result was $488.5 million, up 4.37% from the prior year.
• Gross Profit came in at $135.1 million for Q1 2026 at NovoCure, up from $132.2 million in the prior quarter.
• In the past five years, Gross Profit ranged from a high of $135.1 million in Q1 2026 to a low of $92.0 million in Q2 2023.
• The 5-year median for Gross Profit is $112.4 million (2022), against an average of $111.5 million.
• Across the five-year window, Gross Profit fell 18.09% in 2023 and increased 26.25% in 2024, its largest moves.
• NovoCure's Gross Profit stood at $99.5 million in 2022, then advanced by 1.69% to $101.2 million in 2023, then climbed by 26.25% to $127.8 million in 2024, then rose by 3.44% to $132.2 million in 2025, then climbed by 2.22% to $135.1 million in 2026.
• The last three Gross Profit figures came in at $135.1 million (Q1 2026), $132.2 million (Q4 2025), and $122.5 million (Q3 2025), per Business Quant data.